FDA declines to approve Merck and Eisai's liver cancer combo therapy

[July 08, 2020]  (Reuters) - The U.S. Food and Drug Administration on Wednesday declined to approve a combination of Merck & Co Inc's blockbuster cancer drug Keytruda and Eisai Co Ltd's Lenvima for use in previously untreated patients with liver cancer.

The agency's complete response letter cited lack of sufficient evidence that the combination therapy had a meaningful advantage over available treatments for the condition, the companies said http://pdf.reuters.com/htmlnews/
htmlnews.asp?i=43059c3bf0e37541&
u=urn:newsml:reuters.com:
20200708:nBw9b4BTwa.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.